Zentalis Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Zentalis Pharmaceuticals Llc
ZNTL Stock  USD 2.34  0.09  3.70%   
Zentalis Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Zentalis Pharmaceuticals' valuation are provided below:
Gross Profit
26.9 M
Market Capitalization
157.3 M
Enterprise Value Revenue
7.7683
Revenue
26.9 M
Earnings Share
(2.08)
There are over one hundred nineteen available fundamental gauges for Zentalis Pharmaceuticals, which can be analyzed over time and compared to other ratios. We recommend to confirm Zentalis Pharmaceuticals' prevalent fundamental drivers against the all of the trends between 2010 and 2026.

Zentalis Pharmaceuticals Total Revenue

81.42 Million

Check Zentalis Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Zentalis Pharmaceuticals' main balance sheet or income statement drivers, such as Tax Provision of 167.3 K, Net Interest Income of 469.1 K or Interest Income of 469.1 K, as well as many indicators such as Price To Sales Ratio of 3.49, Dividend Yield of 0.0 or PTB Ratio of 0.7. Zentalis financial statements analysis is a perfect complement when working with Zentalis Pharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with Zentalis Stock
Check out the analysis of Zentalis Pharmaceuticals Correlation against competitors.

Zentalis Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets394.8 M494.9 M219.4 M
Slightly volatile
Other Current Liabilities31.2 M48.5 M17.7 M
Slightly volatile
Total Current Liabilities42.8 M60.6 M25 M
Slightly volatile
Total Stockholder Equity309.1 M387.8 M168.4 M
Slightly volatile
Other Liabilities2.3 M3.1 M2.7 M
Slightly volatile
Property Plant And Equipment Net29.6 M42.8 M15.5 M
Slightly volatile
Accounts Payable9.7 M8.6 M6.3 M
Slightly volatile
Cash35.7 M30.5 M34.1 M
Slightly volatile
Non Current Assets Total60.7 M50.9 M36 M
Slightly volatile
Non Currrent Assets Other6.2 M8.1 M3.9 M
Slightly volatile
Cash And Short Term Investments324.1 M426.7 M177.3 M
Slightly volatile
Net Receivables3 M5.8 M2.2 M
Slightly volatile
Common Stock Total Equity50.4 K53.1 K1.2 M
Slightly volatile
Common Stock Shares Outstanding51.4 M81.7 M35.6 M
Slightly volatile
Liabilities And Stockholders Equity394.8 M494.9 M219.4 M
Slightly volatile
Non Current Liabilities Total36.6 M46.5 M19.8 M
Slightly volatile
Other Current Assets8.7 M11.5 M4.7 M
Slightly volatile
Other Stockholder Equity1.7 B1.6 B486.7 M
Slightly volatile
Total Liabilities79.4 M107.1 M44.8 M
Slightly volatile
Property Plant And Equipment Gross24.3 M47.7 M13.4 M
Slightly volatile
Total Current Assets334.1 M444 M183.4 M
Slightly volatile
Capital Stock60.7 K63.9 K32.9 M
Slightly volatile
Non Current Liabilities Other1.5 M976.4 K875.8 K
Slightly volatile
Net Working Capital293.7 M383.3 M159.4 M
Slightly volatile
Intangible Assets7 M7.9 M8.6 M
Slightly volatile
Common Stock60.7 K63.9 K1.4 M
Slightly volatile
Property Plant Equipment5 M8.9 M3.2 M
Slightly volatile
Short and Long Term Debt Total34.1 M49 M17.2 M
Slightly volatile
Deferred Long Term Liabilities672.8 K756.9 K826.2 K
Slightly volatile
Short Term Debt2 M3.5 M1.4 M
Slightly volatile
Noncontrolling Interest In Consolidated Entity189 K198.9 K16.1 M
Slightly volatile
Short Term Investments385 M387.8 M315.2 M
Slightly volatile
Capital Surpluse830.3 M1.2 B672.8 M
Slightly volatile

Zentalis Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Net Interest Income469.1 K572.7 K425 K
Slightly volatile
Interest Income469.1 K572.7 K425 K
Slightly volatile
Depreciation And Amortization781.1 K1.5 M449.8 K
Slightly volatile
Selling General Administrative105.2 M100.2 M31.4 M
Slightly volatile
Other Operating Expenses187.2 M297.4 M109.8 M
Slightly volatile
Research Development140.4 M192.9 M81.1 M
Slightly volatile
Total Operating Expenses187.2 M297.4 M109.8 M
Slightly volatile
Reconciled Depreciation784.5 K1.5 M451 K
Slightly volatile
Cost Of Revenue901.8 K1.5 M488.4 K
Slightly volatile
Selling And Marketing Expenses1.1 M1.3 M1.4 M
Slightly volatile

Zentalis Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation81.2 M77.4 M22.9 M
Slightly volatile
Begin Period Cash Flow51.6 M35.3 M43.3 M
Pretty Stable
Depreciation781 K1.5 M449.5 K
Slightly volatile
Capital Expenditures241.4 K254.2 K771 K
Pretty Stable
Issuance Of Capital Stock381.3 K401.4 K72.8 M
Slightly volatile
Total Cash From Financing Activities118 K124.2 K70.9 M
Slightly volatile
End Period Cash Flow37.1 M32.9 M35 M
Slightly volatile
Change To Liabilities11.4 M17.9 M7.1 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio3.493.6715.8 K
Slightly volatile
PTB Ratio0.70.7311.1347
Slightly volatile
Days Sales Outstanding29.5731.1312.7 K
Slightly volatile
Book Value Per Share4.574.273.7148
Slightly volatile
Stock Based Compensation To Revenue0.80.90.9803
Slightly volatile
Capex To Depreciation0.190.23.6448
Slightly volatile
PB Ratio0.70.7311.1347
Slightly volatile
EV To Sales3.633.8214.9 K
Slightly volatile
Sales General And Administrative To Revenue1.411.49185
Slightly volatile
Research And Ddevelopement To Revenue2.722.86717
Slightly volatile
Capex To Revenue0.00360.00388.5856
Slightly volatile
Cash Per Share4.624.73.5779
Slightly volatile
Income Quality0.941.180.963
Slightly volatile
Intangibles To Total Assets0.00730.00760.1748
Slightly volatile
Current Ratio5.886.595.7811
Slightly volatile
Tangible Book Value Per Share4.394.273.2855
Slightly volatile
Receivables Turnover12.7412.146.231
Slightly volatile
Shareholders Equity Per Share4.434.273.4378
Slightly volatile
Debt To Equity0.06840.110.062
Slightly volatile
Capex Per Share0.00340.00360.0207
Pretty Stable
Graham Net Net3.53.572.668
Slightly volatile
Revenue Per Share0.90.850.4381
Slightly volatile
Interest Debt Per Share0.460.540.2975
Slightly volatile
Debt To Assets0.05290.08920.0466
Slightly volatile
Operating Cycle29.5731.1312.7 K
Slightly volatile
Price Book Value Ratio0.70.7311.1347
Slightly volatile
Ebt Per Ebit1.051.00.974
Very volatile
Company Equity Multiplier1.471.27631.5052
Slightly volatile
Total Debt To Capitalization0.06170.10.0572
Slightly volatile
Debt Equity Ratio0.06840.110.062
Slightly volatile
Quick Ratio5.886.595.7811
Slightly volatile
Net Income Per E B T0.780.90.9238
Pretty Stable
Cash Ratio0.70.742.7949
Slightly volatile
Cash Conversion Cycle29.5731.1312.7 K
Slightly volatile
Days Of Sales Outstanding29.5731.1312.7 K
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.111.151.0248
Slightly volatile
Price To Book Ratio0.70.7311.1347
Slightly volatile
Fixed Asset Turnover1.711.630.8642
Slightly volatile
Debt Ratio0.05290.08920.0466
Slightly volatile
Price Sales Ratio3.493.6715.8 K
Slightly volatile
Asset Turnover0.150.140.0725
Slightly volatile
Price Fair Value0.70.7311.1347
Slightly volatile

Zentalis Pharmaceuticals Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap1.2 B1.9 B1.3 B
Slightly volatile
Enterprise Value1.1 B1.9 B1.2 B
Slightly volatile

Zentalis Fundamental Market Drivers

Zentalis Upcoming Events

6th of March 2024
Upcoming Quarterly Report
View
8th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
6th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Zentalis Pharmaceuticals Financial Statements

Zentalis Pharmaceuticals investors utilize fundamental indicators, such as revenue or net income, to predict how Zentalis Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue323.1 K339.3 K
Total Revenue77.5 M81.4 M
Cost Of Revenue1.5 M901.8 K
Stock Based Compensation To Revenue 0.90  0.80 
Sales General And Administrative To Revenue 1.49  1.41 
Research And Ddevelopement To Revenue 2.86  2.72 
Revenue Per Share 0.85  0.90 
Ebit Per Revenue(2.55)(2.68)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Prophet
When determining whether Zentalis Pharmaceuticals is a strong investment it is important to analyze Zentalis Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Zentalis Pharmaceuticals' future performance. For an informed investment choice regarding Zentalis Stock, refer to the following important reports:
How To Invest In Zentalis
Details
Is Zentalis Stock a good investment?
Details
What is Zentalis Pharmaceuticals' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Zentalis Pharmaceuticals Correlation against competitors.
You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zentalis Pharmaceuticals. Anticipated expansion of Zentalis directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Zentalis Pharmaceuticals assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share
(2.08)
Revenue Per Share
0.374
Return On Assets
(0.25)
Return On Equity
(0.49)
The market value of Zentalis Pharmaceuticals is measured differently than its book value, which is the value of Zentalis that is recorded on the company's balance sheet. Investors also form their own opinion of Zentalis Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Zentalis Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zentalis Pharmaceuticals' market value can be influenced by many factors that don't directly affect Zentalis Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Zentalis Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Zentalis Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Zentalis Pharmaceuticals' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY